Sign in
Taking people in South KoreaPhase 3

Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney Disease

Tests orforglipron against placebo for heart problems in adults with artery or kidney disease.

Key facts

Who runs it
Eli Lilly and Company
Where
Busan, Daegu, Guri-si, Gwangju, Namdong-gu, Seongnam, Seoul, and Ulsan, South KoreaSee the 16 sitesAlso in 38 other countries, 542 sites
Trial code
Registry title
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Status
Recruiting
Phase
Phase 3
People taking part
7,140 people, planned
Started
1 Dec 2025
Expected to end
Aug 2031
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Orforglipron
  • Placebo
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). It compares orforglipron with placebo and lasts about 5 years.

Age
50 years or older
Sex
All sexes can join
Disease stage
Established ASCVD and/or CKD

Main reasons for not taking part

  • Type 1 diabetes
  • A major heart condition within 60 days before screening
  • New York Heart Association Class IV heart failure

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Have established ASCVD and/or CKD

Who cannot take part

  • Have had a major heart condition within 60 days prior to screening
  • Have type 1 diabetes
  • Have New York Heart Association Functional Classification Class IV heart failure

Where in South Korea

Also in 38 other countries, 542 sites

  • Dong-A University HospitalBusan, South KoreaContact: Jae-Kwan Cha (principal investigator)Taking people
  • Pusan National University Yangsan HospitalBusan, South KoreaContact: Soo Yong Lee (principal investigator)Taking people
  • Daegu Catholic University Medical CenterDaegu, South KoreaContact: SEUNGPYO HONG (principal investigator)Taking people
  • Hanyang University Guri HospitalGuri-si, South KoreaContact: Chang Beom Lee (principal investigator)Taking people
  • Chonnam National University HospitalGwangju, South KoreaContact: Youngkeun Ahn (principal investigator)Taking people
  • Chosun University HospitalGwangju, South KoreaContact: Sang Yong Kim (principal investigator)Taking people
  • Gachon University Gil Medical CenterNamdong-gu, South KoreaContact: Joonpyo Lee (principal investigator)Taking people
  • Seoul National University Bundang HospitalSeongnam, South KoreaContact: IN-HO CHAE (principal investigator)Taking people
  • Asan Medical CenterSeoul, South KoreaContact: KI HOON HAN (principal investigator)Taking people
  • Kangbuk Samsung HospitalSeoul, South KoreaContact: ByungJin Kim (principal investigator)Taking people
  • Korea University Anam HospitalSeoul, South KoreaContact: Soon Jun Hong (principal investigator)Taking people
  • Korea University Guro HospitalSeoul, South KoreaContact: Gang-Jee Ko (principal investigator)Taking people
  • Kyung Hee University Hospital at GangdongSeoul, South KoreaContact: In-Kyung Jeong (principal investigator)Taking people
  • Severance Hospital, Yonsei University Health SystemSeoul, South KoreaContact: Chan Joo Lee (principal investigator)Taking people
  • The Catholic University of Korea Yeouido St. Mary's HospitalSeoul, South KoreaContact: Hyuk-Sang Kwon (principal investigator)Taking people
  • Ulsan University HospitalUlsan, South KoreaContact: GYUNGMIN PARK (principal investigator)Taking people

About the trial

What the trial wants to find out

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

The 2 groups in the trial

  • OrforglipronTreatment being tested

    Participants will receive orforglipron orally + standard of care

  • PlaceboPlacebo, for comparison

    Participants will receive placebo orally + standard of care

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
Plain-language title
Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney DiseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 November 2026